乳腺癌新辅助化疗后病理完全缓解及分子分型的变化与预后的关系

《乳腺癌新辅助化疗后病理完全缓解及分子分型的变化与预后的关系》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153465中国图书分类号R655.8HebeiMedicalUniversity硕士学位论文专业学位乳腺癌新辅助化疗后病理完全缓解及分子分型的变化与预后的关系研究生：帅琰洁导师：马力教授专业：外科学二级学院：第四医院2018年3月目录中文摘要············································································································1英文摘要···································

2、·········································································2英文缩写············································································································3综述乳腺癌新辅助化疗后病理完全缓解及分子分型的变化与预后的关系·······································································

3、·····································4致谢··················································································································19个人简历··········································································································20中文摘要乳腺癌新辅助化疗后病理完全缓解及分

4、子分型的变化与预后的关系摘要新辅助化疗目前已经成为乳腺癌的标准治疗，乳腺癌患者在个体化新辅助化疗后，可以得出患者新辅助化疗后缓解的相关信息以评估患者预后。乳腺癌肿瘤标志物是新辅助治疗决策过程中的关键因素，也是重要的预后指标。目前有研究表明新辅助化疗后达到病理完全缓解（pCR）的患者有较好的预后。而对于未达到pCR的患者，残留病灶的病理特征与预后相关。此外，乳腺癌新辅助治疗前后肿瘤的免疫组化结果可能不同，新辅助治疗后雌激素受体（ER），孕激素受体（PR）和Ki67通常会发生改变，而人表皮生长因子受体2（HER2）较前者更稳定。所有乳腺癌的分子亚型中，三阴性乳腺癌的预后较差，

5、其受体状态在新辅助化疗后最不易转变。而新辅助治疗后乳腺癌分子分型的变化与预后的关系尚不明确。本文将对乳腺癌新辅助化疗后pCR是否可以准确判断预后及残留病灶分子分型变化与预后的关系进行综述。关键词:新辅助化疗，雌激素受体，孕激素受体，人表皮生长因子受体2，Ki67，病理完全缓解,预后1英文摘要PrognosticValueofPathologicCompleteResponseandtheAlterationofBreastCancerImmunohistochemicalBiomarkersafterNeoadjuvantChemotherapyABSTRACTNeoad

6、juvantchemotherapycanprovideinformationaboutthetumor’ssensitivitytochemotherapyandassessindividualizedprognosticsignificancebasedonresponsetotherapy.Thebiomarkersarekeyfactorsinthedecision-makingprocessregardingneoadjuvanttherapyaswellasimportantprognosticindicators.Thepathologiccompleter

7、esponse(pCR)afterNCThasdemonstratedwithanassociatedsurvivalbenefit.ForthepatientswhodonotachievepCR,thepathologiccharacteristicsoftheresidualtumorcanpredictthesurvival.Furthermore,theimmunohistochemical(IHC)markersoftheresidualdiseasesafterprimarysystemictherapymigh